You are here

Home

Clinical Trials: Heart Attack

Each Clinical Trial will open in a new browser window or tab.

Return to Clinical Trials Page

Posted: Friday, June 25, 2021 - 12:00
Treatment of Heart Failure Using Human Umbilical Cord Mesenchymal Stem Cells(hUC-MSC)
Conditions:   Myocardial Ischemia;   Ventricular Dysfunction, Left
Intervention:   Biological: Allogeneic Human Umbilical Cord Mesenchymal Stem Cells
Sponsor:   Shanghai East Hospital
Recruiting
Posted: Monday, March 1, 2021 - 12:00
Allogeneic Mesenchymal Human Stem Cell Infusion Therapy for Endothelial DySfunctiOn in Diabetic Subjects With Symptomatic Ischemic Heart Disease. (ACESO-IHD)
Conditions:   Diabetes Mellitus;   Ischemic Heart Disease
Interventions:   Drug: 100 million Allogeneic Mesenchymal Human Stem Cells;   Other: Placebo
Sponsors:   Joshua M Hare;   National Heart, Lung, and Blood Institute (NHLBI)
Not yet recruiting
Posted: Thursday, January 28, 2021 - 12:00
Heart Patch for Myocardial Infarction COVID-19
Conditions:   Myocardial Infarction;   Heart Diseases
Intervention:   Device: Heart patch seeded with autologous cardiomyocytes and amnion epithelial stem cells
Sponsor:   Rumah Sakit Pusat Angkatan Darat Gatot Soebroto
Not yet recruiting
Posted: Wednesday, September 16, 2020 - 12:00
WJMSCs Anti-inflammatory Therapy in Coronary Artery Disease
Condition:   Coronary Artery Disease
Intervention:   Biological: Intravenous infusion human umbilical Wharton's jelly-derived mesenchymal stem Cell or placebo PBS
Sponsors:   Navy General Hospital, Beijing;   Chinese PLA General Hospital;   Peking University Third Hospital;   Peking Union Medical College Hospital;   Xijing Hospital
Not yet recruiting
Posted: Wednesday, September 16, 2020 - 12:00
WJMSCs Anti-inflammatory Therapy in Acute Myocardial Infarction
Condition:   Acute Myocardial Infarction
Interventions:   Biological: Intravenous infusion placebo;   Biological: Intravenous infusion WJMSCs
Sponsors:   Navy General Hospital, Beijing;   Peking University Third Hospital;   Peking Union Medical College Hospital;   Xijing Hospital;   Chinese PLA General Hospital
Not yet recruiting
Posted: Wednesday, July 22, 2020 - 12:00
RAPA-501-Allo Off-the-Shelf Therapy of COVID-19
Condition:   Severe COVID-19 Disease
Interventions:   Biological: RAPA-501-Allo off-the-shelf Therapy of COVID-19;   Other: Placebo
Sponsors:   Rapa Therapeutics LLC;   Hackensack Meridian Health
Not yet recruiting
Posted: Thursday, May 14, 2020 - 12:00
Feasibility and Safety of Allogeneic Adipose Mesenchymal Stem Cells (aMSCs) Delivery Into Kidney Allografts Procured From Deceased Donors With High Kidney Donor Profile Index (KDPI)
Condition:   Ischemia Reperfusion Injury
Intervention:   Drug: Allogeneic adipose derived mesenchymal stem cells
Sponsor:   Tambi Jarmi
Not yet recruiting
Posted: Thursday, April 9, 2020 - 12:00
Stem Cell in Acute Myocardial Infarction
Condition:   Acute Myocardial Infarction
Intervention:   Biological: Mesenchymal Stem Cells
Sponsor:   PT. Prodia Stem Cell Indonesia
Recruiting
Posted: Tuesday, March 31, 2020 - 12:00
Safety Evaluation of Intracoronary Infusion of Extracellular Vesicles in Patients With AMI
Condition:   Heart Attack
Intervention:   Drug: PEP in Acute Myocardial Infarction
Sponsor:   Paul G. Stalboerger
Not yet recruiting
Posted: Friday, March 13, 2020 - 12:00
Effect of Evolocumab in Patients With Critical Limb Ischemia (Evol-CLI)
Condition:   Critical Limb Ischemia
Interventions:   Drug: Evolocumab 140mg/mL Injector 1milliliter (mL) Pen x 3 for a monthly dose of 420 mg for 12 months.;   Other: Placebo 1 milliliter (mL) Injector Pen x 3 monthly for 12 months
Sponsors:   Leonardo Clavijo;   Amgen
Recruiting

Pages